Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics reports clinical, financial and governance developments for a late-stage biotechnology company developing disease-targeted gene therapy product candidates. Its recurring updates center on 4D-150 for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, and on clinical programs such as 4FRONT, PRISM and SPECTRA.
Company news also covers quarterly and annual financial results, cash runway commentary, collaboration and license revenue tied to Otsuka, investor conference participation, board and leadership changes, and employment inducement equity grants. The company states that its product candidates remain in clinical or preclinical development and have not been approved for marketing by the FDA or other regulatory authorities.
4D Molecular Therapeutics (Nasdaq: FDMT) reported that on May 12, 2026, its board compensation committee granted 141,100 Restricted Stock Units (RSUs) to 14 new non-executive employees.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).
4D Molecular Therapeutics (Nasdaq: FDMT) reported Q1 2026 results and operational updates on May 7, 2026. Key clinical milestones: 4FRONT-1 randomization complete (N=523); 4FRONT-1 topline data expected H1 2027; 4FRONT-2 enrollment expected complete H2 2026 with topline H2 2027. PRISM 2-year data due Q3 2026; SPECTRA 2-year data due H2 2026. Cash, cash equivalents and marketable securities: $458 million as of March 31, 2026, expected to fund operations into H2 2028. Q1 2026 R&D expense: $65.0 million; net loss: $68.8 million.
4D Molecular Therapeutics (Nasdaq: FDMT) announced management will present and hold one-on-one investor meetings at two May 2026 healthcare conferences: BofA Securities 2026 Healthcare Conference on May 13, 2026 at 1:40 p.m. PT, and RBC 2026 Global Healthcare Conference on May 19, 2026 at 2:35 p.m. ET. Archived webcasts will be available for up to one year on the company’s Investors website.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on April 14, 2026 its compensation committee granted a total of 67,600 Restricted Stock Units (RSUs) to five new non-executive employees under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).
The grants were made to induce new employees to join the company and were issued under the amended inducement plan.
4D Molecular Therapeutics (Nasdaq: FDMT) reported full‑year 2025 results and operational milestones, highlighting rapid Phase 3 enrollment for 4D‑150, strategic partnership with Otsuka, and a strengthened balance sheet. Key figures: $514 million cash and marketable securities and an $85 million upfront collaboration payment.
Trials: 4FRONT‑1 enrollment completed early with topline wet AMD data expected H1 2027; PRISM and SPECTRA 2‑year readouts expected mid‑2026 and H2 2026; 4D‑150 DME Phase 3 to start Q3 2026.
4D Molecular Therapeutics (Nasdaq: FDMT) said management will present and hold one-on-one investor meetings at upcoming conferences in March 2026.
Scheduled events include the Leerink Partners Mountain Meeting (March 22–25, 2026) and a presentation at the RBC Capital Markets Global Ophthalmology Conference on March 24, 2026 at 3:45 p.m. GMT. An archived webcast will be available for up to one year on the company Investors site.
4D Molecular Therapeutics (Nasdaq: FDMT) said management will present and hold one-on-one investor meetings at three healthcare conferences in March 2026.
Presentations are scheduled at TD Cowen on March 3, 2026 at 10:30 a.m. ET, Leerink on March 10, 2026 at 4:20 p.m. ET, and Barclays on March 12, 2026 at 9:00 a.m. ET. Webcasts will be archived for up to one year on the company Investors site.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on February 10, 2026 its compensation committee granted 124,200 Restricted Stock Units (RSUs) to nine new non-executive employees under the Company’s 2025 Employment Inducement Award Plan.
The awards were made pursuant to Rule 5635(c)(4) of The Nasdaq Global Market to induce new employees to join the company.
4D Molecular Therapeutics (Nasdaq: FDMT) announced completion of enrollment for 4FRONT-1, the first Phase 3 registrational trial of 4D-150 in wet age-related macular degeneration (wet AMD), achieved in approximately 11 months and with over-enrollment expected to exceed 500 randomized patients.
Topline primary endpoint data for 4FRONT-1 is expected in H1 2027; global activation for 4FRONT-2 continues with enrollment on track for completion in H2 2026 and topline data expected in H2 2027.
4D Molecular Therapeutics (Nasdaq: FDMT) announced on January 17, 2026 that its compensation committee granted 23,600 Restricted Stock Units (RSUs) on January 13, 2026 to four new non-executive employees.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan, which the board approved in February 2025 under Nasdaq Rule 5635(c)(4) to permit equity grants that induce new hires to join the company.